Skip to main content
SpringerLink
Log in

Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

The introduction of agents such as thalidomide, lenalidomide, and bortezomib has changed the management of patients with multiple myeloma who are not eligible for autologous transplantation, many of whom are elderly. We sought to compare three thalidomide-based oral regimens among such patients in Latin America. We randomized patients with newly diagnosed multiple myeloma with measurable disease to one of the following regimens: melphalan, prednisone, and thalidomide (MPT); cyclophosphamide, thalidomide, and dexamethasone (CTD); and thalidomide and dexamethasone (TD). The TD arm was closed prematurely and was analyzed only descriptively. The primary endpoint was the overall response rate (ORR), whereas progression-free survival (PFS) and overall survival (OS) were secondary endpoints. The accrual rate was slower than expected, and the study was terminated after 82 patients had been randomized. The ORRs were 67.9 % with MPT, 89.7 % with CTD, and 68.7 % with TD (p = 0.056 for the comparison between MPT and CTD). The median PFS was 24.1 months for MPT, 25.9 months for CTD, and 21.5 months for TD. There were no statistically significant differences in PFS or OS between MPT and CTD. In an unplanned logistic regression analysis, ORR was significantly associated with treatment with CTD (p = 0.046) and with performance status of 0 or 1 (p = 0.035). Based on the current results, no definitive recommendations can be made regarding the comparative merit of the regimens tested. Nevertheless and until the results of further studies become available, we recommend either CTD or MPT as suitable frontline regimens for patients with multiple myeloma who are not candidates to transplantation in settings where lenalidomide and bortezomib are not available.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ailawadhi S, Aldoss IT, Yang D, Razavi P, Cozen W, Sher T, Chanan-Khan A (2012) Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups. Br J Haematol 158(1):91–98. doi:10.1111/j.1365-2141.2012.09124.x

    Article  PubMed  Google Scholar 

  2. Myeloma Trialists’ Collaborative Group (1998) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 16(12):3832–3842

    Google Scholar 

  3. Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364(11):1046–1060. doi:10.1056/NEJMra1011442

    Article  PubMed  CAS  Google Scholar 

  4. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, Cangialosi C, Grasso M, Rossini F, Galli M, Catalano L, Zamagni E, Petrucci MT, De Stefano V, Ceccarelli M, Ambrosini MT, Avonto I, Falco P, Ciccone G, Liberati AM, Musto P, Boccadoro M (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367(9513):825–831. doi:10.1016/S0140-6736(06)68338-4

    Article  PubMed  CAS  Google Scholar 

  5. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, Renaud M, Harousseau JL, Guillerm G, Chaleteix C, Dib M, Voillat L, Maisonneuve H, Troncy J, Dorvaux V, Monconduit M, Martin C, Casassus P, Jaubert J, Jardel H, Doyen C, Kolb B, Anglaret B, Grosbois B, Yakoub-Agha I, Mathiot C, Avet-Loiseau H (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial. Lancet 370(9594):1209–1218. doi:10.1016/S0140-6736(07)61537-2

    Article  PubMed  CAS  Google Scholar 

  6. Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Bjorkstrand B, Carlson K, Dahl IM, Forsberg K, Gulbrandsen N, Haukas E, Hjertner O, Hjorth M, Karlsson T, Knudsen LM, Nielsen JL, Linder O, Mellqvist UH, Nesthus I, Rolke J, Strandberg M, Sorbo JH, Wisloff F, Juliusson G, Turesson I, Nordic Myeloma Study G (2010) Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 116(9):1405–1412. doi:10.1182/blood-2009-08-237974

    Article  PubMed  CAS  Google Scholar 

  7. Beksac M, Haznedar R, Firatli-Tuglular T, Ozdogu H, Aydogdu I, Konuk N, Sucak G, Kaygusuz I, Karakus S, Kaya E, Ali R, Gulbas Z, Ozet G, Goker H, Undar L (2011) Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol 86(1):16–22. doi:10.1111/j.1600-0609.2010.01524.x

    Article  PubMed  CAS  Google Scholar 

  8. Verelst SG, Termorshuizen F, Uyl-de Groot CA, Schaafsma MR, Ammerlaan AH, Wittebol S, Sinnige HA, Zweegman S, van Marwijk Kooy M, van der Griend R, Lokhorst HM, Sonneveld P, Wijermans PW, Dutch-Belgium Hemato-Oncology Cooperative G (2011) Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial. Ann Hematol 90(12):1427–1439. doi:10.1007/s00277-011-1224-1

    Article  PubMed  CAS  Google Scholar 

  9. Sacchi S, Marcheselli R, Lazzaro A, Morabito F, Fragasso A, Di Renzo N, Balleari E, Neri S, Quarta G, Ferrara R, Vigliotti ML, Polimeno G, Musto P, Consoli U, Zoboli A, Buda G, Pastorini A, Masini L (2011) A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant. Leuk Lymphoma 52(10):1942–1948. doi:10.3109/10428194.2011.584006

    Article  PubMed  CAS  Google Scholar 

  10. Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksac M, Bringhen S, Mary JY, Gimsing P, Termorshuizen F, Haznedar R, Caravita T, Moreau P, Turesson I, Musto P, Benboubker L, Schaafsma M, Sonneveld P, Facon T (2011) Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 118(5):1239–1247. doi:10.1182/blood-2011-03-341669

    Article  PubMed  CAS  Google Scholar 

  11. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359(9):906–917. doi:10.1056/NEJMoa0801479

    Article  PubMed  CAS  Google Scholar 

  12. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jedrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Blade J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA (2012) Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 366(19):1759–1769. doi:10.1056/NEJMoa1112704

    Article  PubMed  CAS  Google Scholar 

  13. Lopes LC, Barberato-Filho S, Costa AC, Osorio-de-Castro CG (2010) Rational use of anticancer drugs and patient lawsuits in the state of Sao Paulo, Southeastern Brazil. Rev Saude Publica 44(4):620–628

    Article  PubMed  Google Scholar 

  14. Garcia-Sanz R, Gonzalez-Porras JR, Hernandez JM, Polo-Zarzuela M, Sureda A, Barrenetxea C, Palomera L, Lopez R, Grande-Garcia C, Alegre A, Vargas-Pabon M, Gutierrez ON, Rodriguez JA, San Miguel JF (2004) The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 18(4):856–863. doi:10.1038/sj.leu.2403322 2403322

    Article  PubMed  CAS  Google Scholar 

  15. Morgan GJ, Davies FE, Gregory WM, Russell NH, Bell SE, Szubert AJ, Navarro Coy N, Cook G, Feyler S, Byrne JL, Roddie H, Rudin C, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA (2011) Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood 118(5):1231–1238. doi:10.1182/blood-2011-02-338665

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  16. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24(3):431–436. doi:10.1200/JCO.2005.03.0221

    Article  PubMed  CAS  Google Scholar 

  17. Ludwig H, Hajek R, Tothova E, Drach J, Adam Z, Labar B, Egyed M, Spicka I, Gisslinger H, Greil R, Kuhn I, Zojer N, Hinke A (2009) Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 113(15):3435–3442. doi:10.1182/blood-2008-07-169565

    Article  PubMed  CAS  Google Scholar 

  18. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV (2006) International uniform response criteria for multiple myeloma. Leukemia 20(9):1467–1473. doi:10.1038/sj.leu.2404284

    Article  PubMed  CAS  Google Scholar 

  19. Rajkumar SV, Rosinol L, Hussein M, Catalano J, Jedrzejczak W, Lucy L, Olesnyckyj M, Yu Z, Knight R, Zeldis JB, Blade J (2008) Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 26(13):2171–2177. doi:10.1200/JCO.2007.14.1853

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  20. Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, Anderson K, Fermand JP, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C, Facon T, Team FT (2014) Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 371(10):906–917. doi:10.1056/NEJMoa1402551

    Article  PubMed  CAS  Google Scholar 

  21. Wildes TM, Rosko A, Tuchman SA (2014) Multiple myeloma in the older adult: better prospects, more challenges. J Clin Oncol 32(24):2531–2540. doi:10.1200/JCO.2014.55.1028

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

We thank María-Victoria Mateos (Hospital Universitario de Salamanca, Spain) and Jesús F San-Miguel (Clínica Universidad de Navarra-CIMA, Pamplona, Spain) for their contributions to this study.

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Santa Casa de São Paulo Medical School, Rua Marquês de Itu, 579—3° andar, CEP 01223-001, São Paulo, Brazil

    V. T. M. Hungria, E. Q. Crusoé, M. S. S. Almeida, P. Cury, F. Hisgashi, A. L. Peres & C. S. Chiattone

  2. Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

    A. Maiolino & R. J. Pessoa de Magalhaes

  3. Universidade Federal de Porto Alegre, Porto Alegre, Brazil

    R. Bittencourt

  4. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

    D. Fantl

  5. Liga Norte-Riograndense Contra o Câncer, Natal, Brazil

    J. F. R. Maciel

Authors
  1. V. T. M. Hungria
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Q. Crusoé
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Maiolino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Bittencourt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Fantl
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. F. R. Maciel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. J. Pessoa de Magalhaes
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. S. S. Almeida
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P. Cury
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. F. Hisgashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A. L. Peres
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. C. S. Chiattone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V. T. M. Hungria.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hungria, V.T.M., Crusoé, E.Q., Maiolino, A. et al. Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible. Ann Hematol 95, 271–278 (2016). https://doi.org/10.1007/s00277-015-2537-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-015-2537-2

Keywords

Search

Navigation